Alpha Cognition (NASDAQ:ACOG) Posts Earnings Results, Misses Estimates By $0.03 EPS

Alpha Cognition (NASDAQ:ACOG) released its quarterly earnings data on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03), Zacks reports. Alpha Cognition had a negative net margin of 202.23% and a negative return on equity of 68.21%. The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $4.41 million.

Here are the key takeaways from Alpha Cognition’s conference call:

• Strong early commercial traction — Q4 dispensed 4,941 bottles (1,859 in December), Q4 net product revenue of $2.5M and YTD product sales of $6.8M, with prescribers up 50% vs Q3 and high repeat ordering (82% of ordering homes).
• Payer progress — executed a second national PBM contract (now contracted with 2 of the top 4 PBMs); company expects downstream plan-level pull-through beginning in Q2 with broader implementation in Q3, though payer access remains a material friction point.
• Clinical and safety momentum — management reports minimal spontaneous GI adverse events, launched three real‑world studies (BEACON, CONVERGE, RESOLVE) with toplines in Q3–Q4 2026, and plans a sublingual PK study in Q2 targeting clinic entry in early 2027.
• Financial posture reflects heavier investment — FY2025 operating loss widened; 2026 operating expenses expected at $54–58M; the company holds approximately $66M in cash (post raise) providing runway into 2027 while targeting operational profitability in 2027.
• Commercial scaling initiatives — sales force expansion is largely filled, nearly 3,856 unique homes reached to date, and 48 KOLs trained for national peer‑to‑peer education intended to accelerate adoption in long‑term care.

Alpha Cognition Stock Down 4.9%

Shares of Alpha Cognition stock opened at $5.08 on Friday. The business has a 50 day moving average of $5.57 and a 200 day moving average of $6.28. The company has a market cap of $110.44 million, a PE ratio of -4.38 and a beta of 2.55. Alpha Cognition has a 52 week low of $3.75 and a 52 week high of $11.54.

Institutional Investors Weigh In On Alpha Cognition

Several institutional investors have recently bought and sold shares of ACOG. Opaleye Management Inc. increased its holdings in shares of Alpha Cognition by 1,698.5% during the 4th quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock worth $13,460,000 after buying an additional 1,955,642 shares during the last quarter. AWM Investment Company Inc. lifted its position in shares of Alpha Cognition by 52.6% during the fourth quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock worth $10,869,000 after purchasing an additional 576,516 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in Alpha Cognition in the 4th quarter valued at approximately $2,372,000. Cable Car Capital LP increased its holdings in Alpha Cognition by 68.8% during the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after purchasing an additional 354,278 shares during the period. Finally, Sphera Funds Management LTD. raised its holdings in Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock valued at $3,690,000 after acquiring an additional 228,864 shares in the last quarter.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Alpha Cognition in a research report on Friday, December 19th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $18.00.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.